{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:49:30Z","timestamp":1779317370867,"version":"3.51.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010825","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000}}],"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["RP-2017-08-ST2-012"],"award-info":[{"award-number":["RP-2017-08-ST2-012"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["TRIA2015-1092"],"award-info":[{"award-number":["TRIA2015-1092"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Global Health Trials","award":["MR\/P006922\/1"],"award-info":[{"award-number":["MR\/P006922\/1"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The AMBITION-cm trial for HIV-associated cryptococcal meningitis demonstrated that a single, high-dose of liposomal amphotericin (AmBisome) plus 14-days of oral flucytosine and fluconazole was non-inferior in terms of all-cause mortality to 7-days of amphotericin B deoxycholate and flucytosine followed by 7-days of fluconazole (Control). The AmBisome regimen was associated with fewer adverse events. We explored the acceptability of the AmBisome regimen from the perspective of participants and providers.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We embedded a qualitative methods study within the AMBITION-cm sites in Botswana and Uganda. We conducted in-depth interviews with trial participants, surrogate decision makers, and researchers and combined these with direct observations. Interviews were transcribed, translated, and analysed thematically.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We interviewed 38 trial participants, 20 surrogate decision makers, and 31 researchers. Participant understanding of the trial was limited; however, there was a preference for the AmBisome regimen due to the single intravenous dose and fewer side effects. More time was required to prepare the single AmBisome dose but this was felt to be acceptable given subsequent reductions in workload. The AmBisome regimen was reported to be associated with fewer episodes of rigors and thrombophlebitis and a reduction in the number of intravenous cannulae required. Less intensive monitoring and management was required for participants in the AmBisome arm.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The AmBisome regimen was highly acceptable, being simpler to administer despite the initial time investment required. The regimen was well tolerated and associated with less toxicity and resultant management. Widespread implementation would reduce the clinical workload of healthcare workers caring for patients with HIV-associated cryptococcal meningitis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0010825","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:32:33Z","timestamp":1666632753000},"page":"e0010825","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-4039","authenticated-orcid":true,"given":"David S.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Ssali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neo","family":"Moshashane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Nabaggala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lebogang","family":"Maphane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"pntd.0010825.ref001","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","author":"R Rajasingham","year":"2022","journal-title":"The Lancet Infectious Diseases"},{"issue":"5","key":"pntd.0010825.ref002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/cid\/cix430","article-title":"Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis.","volume":"65","author":"MW Tenforde","year":"2017","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"suppl_2","key":"pntd.0010825.ref003","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cix1140","article-title":"The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa","volume":"66","author":"M Osler","year":"2018","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"suppl_2","key":"pntd.0010825.ref004","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/cid\/ciy045","article-title":"Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa\u2019s National HIV Program: Data From a Nationwide Laboratory Cohort","volume":"66","author":"S Carmona","year":"2018","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"pntd.0010825.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12951","article-title":"Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.","volume":"22","author":"TB Leeme","year":"2021","journal-title":"HIV medicine."},{"issue":"11","key":"pntd.0010825.ref006","doi-asserted-by":"crossref","first-page":"e110285","DOI":"10.1371\/journal.pone.0110285","article-title":"A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.","volume":"9","author":"KM Gaskell","year":"2014","journal-title":"PloS one"},{"issue":"12","key":"pntd.0010825.ref007","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.","volume":"47","author":"N Longley","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"6","key":"pntd.0010825.ref008","doi-asserted-by":"crossref","first-page":"e67311","DOI":"10.1371\/journal.pone.0067311","article-title":"A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.","volume":"8","author":"C Rothe","year":"2013","journal-title":"PloS one"},{"issue":"3","key":"pntd.0010825.ref009","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.","volume":"50","author":"JC Nussbaum","year":"2010","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"11","key":"pntd.0010825.ref010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa","volume":"378","author":"SF Molloy","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"6","key":"pntd.0010825.ref011","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis","volume":"374","author":"J Beardsley","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"12","key":"pntd.0010825.ref012","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1128\/AAC.01698-15","article-title":"Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis","volume":"59","author":"T Bicanic","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"pntd.0010825.ref013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-019-4209-7","article-title":"Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.","volume":"19","author":"C Ahimbisibwe","year":"2019","journal-title":"BMC infectious diseases."},{"issue":"Suppl 4","key":"pntd.0010825.ref014","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.","volume":"68","author":"J Adler-Moore","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"Suppl 4","key":"pntd.0010825.ref015","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.","volume":"68","author":"AH Groll","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"2","key":"pntd.0010825.ref016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.","volume":"51","author":"RJ Hamill","year":"2010","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"key":"pntd.0010825.ref017","article-title":"Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial","author":"JN Jarvis","year":"2018","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"pntd.0010825.ref018","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"S Sundar","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"9","key":"pntd.0010825.ref019","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.01448-08","article-title":"Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg\/kg), weekly dose (7.5 mg\/kg), or daily dose (1 mg\/kg) in peripheral stem cell transplant patients.","volume":"53","author":"PO Gubbins","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"1","key":"pntd.0010825.ref020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s13063-018-3026-4","article-title":"AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.","volume":"19","author":"DS Lawrence","year":"2018","journal-title":"Trials."},{"issue":"12","key":"pntd.0010825.ref021","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.","volume":"386","author":"JN Jarvis","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"pntd.0010825.ref022","volume-title":"Guidelines for diagnosis, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.","author":"World Health Organisation","year":"2022"},{"issue":"4","key":"pntd.0010825.ref023","doi-asserted-by":"crossref","first-page":"e039191","DOI":"10.1136\/bmjopen-2020-039191","article-title":"The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis.","volume":"11","author":"DS Lawrence","year":"2021","journal-title":"BMJ open"},{"issue":"2","key":"pntd.0010825.ref024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"V Braun","year":"2006","journal-title":"Qualitative Research in Psychology"},{"key":"pntd.0010825.ref025","doi-asserted-by":"crossref","first-page":"115082","DOI":"10.1016\/j.socscimed.2022.115082","article-title":"Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception.","volume":"305","author":"DS Lawrence","year":"2022","journal-title":"Social Science & Medicine."},{"issue":"1","key":"pntd.0010825.ref026","doi-asserted-by":"crossref","first-page":"e25416","DOI":"10.1002\/jia2.25416","article-title":"Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis","volume":"23","author":"MW Tenforde","year":"2020","journal-title":"Journal of the International AIDS Society"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010825","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:53:33Z","timestamp":1667498013000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010825"}},"subtitle":[],"editor":[{"given":"Chaoyang","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010825","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0010825","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}